Illumina, Inc. (NASDAQ:ILMN) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of Illumina, Inc. (NASDAQ:ILMN) have received an average rating of “Hold” from the twenty-one ratings firms that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, ten have issued a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $140.90.

A number of analysts have weighed in on the stock. Robert W. Baird reduced their price objective on shares of Illumina from $127.00 to $90.00 and set a “neutral” rating for the company in a research note on Wednesday, March 5th. HSBC downgraded Illumina from a “buy” rating to a “hold” rating and set a $100.00 price target for the company. in a research note on Friday, February 28th. Hsbc Global Res cut shares of Illumina from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 28th. TD Cowen lowered shares of Illumina from a “buy” rating to a “hold” rating and cut their target price for the company from $177.00 to $140.00 in a research report on Friday, February 7th. Finally, Guggenheim decreased their price target on shares of Illumina from $170.00 to $150.00 and set a “buy” rating on the stock in a research report on Friday, February 7th.

Illumina Trading Down 3.0 %

NASDAQ:ILMN opened at $74.16 on Friday. The firm has a market capitalization of $11.75 billion, a P/E ratio of -9.66, a PEG ratio of 1.60 and a beta of 1.38. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42. Illumina has a one year low of $70.64 and a one year high of $156.66. The company’s 50-day simple moving average is $96.82 and its 200 day simple moving average is $125.10.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. As a group, analysts forecast that Illumina will post 4.51 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in ILMN. 111 Capital bought a new stake in shares of Illumina during the fourth quarter valued at approximately $223,000. Wealth Enhancement Advisory Services LLC grew its stake in Illumina by 13.6% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 20,197 shares of the life sciences company’s stock valued at $2,699,000 after acquiring an additional 2,421 shares in the last quarter. PKO Investment Management Joint Stock Co bought a new stake in Illumina in the 4th quarter valued at $200,000. Probity Advisors Inc. lifted its stake in Illumina by 12.2% in the 4th quarter. Probity Advisors Inc. now owns 2,054 shares of the life sciences company’s stock worth $274,000 after purchasing an additional 224 shares in the last quarter. Finally, Siemens Fonds Invest GmbH boosted its holdings in shares of Illumina by 84.8% during the 4th quarter. Siemens Fonds Invest GmbH now owns 6,119 shares of the life sciences company’s stock valued at $818,000 after purchasing an additional 2,807 shares during the last quarter. 89.42% of the stock is owned by hedge funds and other institutional investors.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.